EWTX’s EDG-7500 Shows Superior Efficacy in Both Studies. Per the data readout from the phase I study in healthy adults, no meaningful changes in left ventricle ejection fraction ...

Below is a chart showing EWTX's trailing twelve month trading history, with the $25 strike highlighted in orange: For the various different available expirations for NBIX options, ACLS options, or ...

EWTX is evaluating EDG-7500, a novel oral, selective, cardiac sarcomere modulator with a unique mechanism of action, in the ongoing phase II CIRRUS-HCM study. The latest data readout is from Part ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company, focuses on developing therapies for the treatment of muscle disorders.

Edgewise Therapeutics, Inc. (EWTX) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or "the Company") ...

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price target of $45.00. The company’s shares closed ...

Edgewise Therapeutics (EWTX) is scheduled to report earnings on February 20, 2025. The last reported earnings were for reported on November 7, 2024 for Q3. Q ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for EWTX is 70.

Earlier this month, John R. Moore, the GC of EWTX sold 70,922.00 shares for a total of $1,996,365.64. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing ...